Print
PROVEN EFFICACY
AND SAFETY
Proven efficacy in two large clinical studies in cats
Treatment success defined as a cat not requiring rescue* analgesia during the 72-hour observation period1
SIMBADOL administered subcutaneously once daily on days 1 (60 minutes before surgery), 2 and 31
* A rescue protocol was implemented when a cat was assessed as being uncomfortable or painful. The rescue protocol included meloxicam (0.1 mg/kg. SC). If additional analgesia was required, hydromorphone (0.3 mg/kg, SC) was administered.
Treatment success in feline soft tissue surgery1,3
Randomized, double-blind, placebo-controlled, parallel group study. A total of 221 cats at 19 sites in the US received either a subcutaneous injection of 0.24 mg/kg of SIMBADOL™ (buprenorphine injection) or physiologic saline approximately 60 minutes prior to surgery, at the same time as preanesthetic medication. Subsequent once-daily doses were given at 24 hours and 48 hours after the initial treatment. Treatment success was defined as a cat that made it through an entire 72-hour period without rescue analgesia.3
Treatment success in feline orthopedic surgery1,4
Randomized, double-blind, placebo-controlled, parallel group study. A total of 221 cats at 19 sites in the US received either a subcutaneous injection of 0.24 mg/kg of SIMBADOL™ (buprenorphine injection) or physiologic saline approximately 60 minutes prior to surgery, at the same time as preanesthetic medication. Subsequent once-daily doses were given at 24 hours and 48 hours after the initial treatment. Treatment success was defined as a cat that made it through an entire 72-hour period without rescue analgesia.4
*Orthopedic surgical procedures included onychectomy, onychectomy and castration, or onychectomy and ovariohysterectomy.1,3
Safety profile established
In the Soft Tissue and Orthopedic Surgery studies, the majority of adverse events were either typical opioid reactions or were similar to the placebo group in frequency.2 Adverse reactions may include hyperthermia, tachycardia, hypotension, hypertension, hypothermia, anorexia, and hyperactivity.
Target animal safety study demonstrated safety
Well tolerated at up to 5x the labeled dose for up to 9 days6
In a 9-day target animal safety study, 4-month-old healthy cats (4/sex/group; n=32) were administered SIMBADOL™ (buprenorphine injection) subcutaneously at 0X (saline), 1X (0.24 mg/kg), 3X (0.72 mg/kg) or 5X (1.2 mg/kg) once daily.1
“Zoetis recommends use at label dose of 0.24 mg/kg and duration of up to 3 days.”
Surgical blood pressure study showed no effect on blood pressure
There were no differences in mean blood pressure between groups1,6
Arterial blood pressure was assessed in a study of 16 healthy 8.5- to 29.1-month-old cats (4/sex/group) who were subcutaneously administered SIMBADOL™ (buprenorphine injection) at 0.24 mg/kg (1X) or meloxicam (control), one hour prior to anesthetic induction for a 1-hour exploratory laparotomy. Arterial blood pressure was monitored following anesthetic induction and through laparotomy, with indirect blood pressure monitoring prior to anesthesia and for 8 hours following anesthetic recovery.1
Try SIMBADOL Today
CONTACT US
United States 
For animals. For health. For you.
This site is intended for U.S. Animal Healthcare Professionals. The product information provided in this site is intended only for residents of the United States. The products discussed herein may not have marketing authorization or may have different product labeling in different countries. The animal health information contained herein is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. All decisions regarding the care of a veterinary patient must be made with an animal healthcare professional, considering the unique characteristics of the patient.
All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. ©2021 Zoetis Services LLC. All rights reserved.
